Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics. These engineered therapies are designed to selectively engage and modulate targeted T cells, mimicking nature's signals to expand and activate specific immune cells while restoring immune balance. The company's platform addresses serious diseases by mobilizing the patient's own immune system for precise therapeutic responses. Operating within the biotechnology industry and pharmaceuticals & biotech sector, Cue Biopharma, Inc. advances its programs through clinical development, emphasizing innovative biologics that offer potential in immunotherapy applications. Founded in 2014 and headquartered in Boston, Massachusetts, the company concentrates on creating targeted treatments that harness immune mechanisms to combat disease, positioning it as a key player in the evolving landscape of immune-oncology and related therapeutic areas.